Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
This article was originally published in The Pink Sheet Daily
Executive Summary
Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.